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vasculopathy: clinical characteristics 
and surgical outcomes
Vitreous hemorrhage in PCV
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Abstract 
Background: To report the outcomes of vitreous hemorrhage (VH) associated with hemorrhagic polypoidal choroi-
dal vasculopathy (PCV).
Methods: A retrospective study of 28 eyes of 27 consecutive patients of hemorrhagic PCV with VH, which were man-
aged surgically between January 2003 and December 2011, was performed. All patients underwent pars plana vitrec-
tomy for VH associated with PCV. The main outcome measure was best-corrected visual acuity (BCVA) at baseline, at 1, 
3 and 6 months post operatively and at last follow up.
Results: The visual acuity measured on early treatment diabetic retinopathy study (ETDRS) chart improved in 16 eyes 
(57.1 %) by two or more lines, remained unchanged in nine eyes (32.1 %) and decreased in three (10.7 %) after surgery 
when compared to baseline VA. The mean baseline VA was 2.69 ± 0.57 logMAR units (<20/2000) which improved 
to 1.65 ± 0.93 logMAR units (20/800) at 1 month post operative visit and was sustained at 1.72 ± 1.12 (20/800) with 
an improvement of 0.96 logMAR units (p < 0.001, 95 % CI 0.54–1.37). The average postoperative follow up was for 
14.2 months (range 1–84). The complications noted in postoperative follow up were cataract (n = 10), macular scar-
ing (n = 9), organised dehemoglobinised blood (n = 7), retinal tear or detachment (n = 5), recurrent VH (n = 3) and 
choroidal detachment (n = 1).
Conclusion: Majority of patients with loss of vision due to VH secondary to hemorrhagic PCV have sustained 
improvement in visual acuity following surgery.
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Background
Polypoidal choroidal vasculopathy (PCV) is a persistent 
and chronic disease with a variable course [1]. Although 
the prognosis of PCV is commonly reported to be more 
favorable and the clinical course more stable as compared 
with exudative age-related macular degeneration (AMD) 
[2–4], the natural history of PCV, especially haemor-
rhagic PCV, is not clearly known and may not be as 
benign as previously reported [1].
The primary abnormality in PCV involves the choroi-
dal circulation, and the characteristic lesion is an inner 
choroidal vascular network of vessels ending in an aneu-
rysmal bulge or outward projection seen clinically as 
reddish orange polyps [5]. Leakage in the vessel wall at 
dilatations leads to serous pigment epithelial detach-
ments (PED) and lipid deposition in the exudative form 
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of PCV while recurrent serosanguinous detachments of 
the retinal pigment epithelium and neurosensory retina 
are the predominant manifestation of hemorrhagic PCV. 
Massive hemorrhages may develop from rupture of ven-
ules and occasionally arteries. Sequelae of this is a sud-
den onset severe visual loss due to break through vitreous 
hemorrhage (VH) [1, 6–10].
About half the cases of PCV have a stable course and 
relatively favorable visual outcome, while the others have 
persistent leakage, repeated haemorrhages and poor vis-
ual outcome [1, 4]. Profound visual loss in hemorrhagic 
PCV primarily results from recurrent serosanguinous 
haemorrhagic detachments involving the fovea or recur-
rent VH.
There is a lack of understanding of hemorrhagic PCV 
and there are very few reports in the literature on the 
outcomes of conservative [1, 4], or surgical management 
of PCV with VH [4, 6]. In the current study we report the 
incidence, clinical characteristics, management and sur-
gical outcome in haemorrhagic PCV presenting with vit-
reous haemorrhage.
Methods
This study was a retrospective, interventional consecu-
tive case series. The study was approved by the local eth-
ics committee of L.V. Prasad Eye Institute (LEC-11-160) 
and all participants gave consent for using patient data 
for research purpose. Medical records of all cases hav-
ing a diagnosis ICD coding of PCV and vitreous haemor-
rhage who underwent pars plana vitrectomy (PPV) were 
identified and studied. Twenty-eight eyes of 27 consecu-
tive patients treated surgically for PCV associated with 
VH were included.
Due to the presence of VH, the media clarity did not 
allow the visualization of the fundus or angiography in 
most eyes at presentation. Although the EVEREST trial 
laid down guidelines for the diagnosis of PCV [11], mas-
sive hemorrhagic PCV may not show the same features 
at presentation in the affected eye. The vitreous haemor-
rhage was attributed to PCV on the basis of preoperative 
B-scan features [6], and confirmed with demonstration 
of polypoidal lesions and/or branching vascular network 
in the study or fellow eye on indocyanine angiography 
(ICGA) in the past or post-operatively, as laid down in 
the EVEREST trial [11]. Patients were excluded if the 
same or fellow eye had any other vascular or degenerative 
retinal or macular condition, or any other ocular pathol-
ogy which could limit their vision.
After a preoperative written informed consent all 
patients underwent standard 20 or 23 gauge PPV. Removal 
of subretinal blood was not attempted in this series.
The data pertaining to age, gender, duration of diabetes 
and hypertension, duration of symptoms, best-corrected 
visual acuity (BCVA) at presentation, 1, 3, 6 months post-
operative and at the last follow up, intraocular pressure 
(IOP, Goldman applanation tonometry), surgical proce-
dures performed, surgical complications and duration of 
follow up were collected and are summarized in Table 1.
The primary outcome measure of this series was the 
number of patients who improved by two or more lines 
on early treatment diabetic retinopathy study (ETDRS) 
chart after surgery. Secondary outcome measures were 
mean change in logMAR visual acuity, and complications 
of surgery.
The visual improvement post operatively and the differ-
ences between BCVA at 1 month post operative visit and 
final follow up from the baseline pre operative visual acu-
ity were compared using paired t test. Statistical analysis 
was done using Statistical software R, version 2.14.1.
Results
Twenty-eight eyes of 27 patients (21 men, 6 women) with 
a mean age of 58.89 ± 13.13 years (range 36–82) under-
went PPV for vitreous haemorrhage associated with PCV 
between January 2003 and December 2011. Their base-
line demographic characteristics are shown in Table  1. 
Ten (37 %) patients had a history of diabetes mellitus for 
an average of 13 years (range 3–25 years) and 16 (59 %) 
patients had a history of hypertension for an average 
10.5 years (range 1–36).
Table 1 Demographic and baseline characteristics
PCV polypoidal choiroidal vasculopathy, VH vitreous hemorrhage, DM diabetes 
mellitus, VR vitreoretinal, IVB intravitreal bevacizumab, PDT photodynamic 
therapy, IVTA intravitreal triamcinolone acetonide, PED pigment epithelial 
detachment
1. No of eyes 28
2. Age (mean) 58.89 years (range 36–82)
3. Gender 22 males, 6 females
4. Bilateral PCV + VH 4 (14.28 %)
5. DM/duration 10 patients/13 years (range 
3–25 years)
6. Hypertension/duration 15 patients/10.5 years (range 
1–36 years)
7. Eye 13 OD, 15 OS
8. Duration of symptoms in 
months
6.2 (range 1–48 months)
9. Lens status 11 phakic, 6 pseudophakic, 1 
aphakic
10. Previous treatment VR surgery (n = 3), IVB (n = 5), 
PDT (n = 3),  
Laser (n = 1), IVTA (n = 1), Oral 
steroids (n = 3)
11. Fundus exam at  
presentation
No view (n = 21), hemorrhagic 
PED (n = 6),  
subretinal blood (n = 4), pig-
mentary changes (n = 1)
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The mean duration of symptoms at presentation was 
6.2  ±  3.3  months with sudden onset profound painless 
diminution of vision being the most common presenting 
complaint. The mean preoperative baseline logMAR visual 
acuity was 2.69 ± 0.58 (<20/2000, range 20/400 to percep-
tion of light, PL). At 1 month postoperative follow up, the 
mean BCVA was 1.69 ± 0.93 (20/979, range 20/20 to PL) 
with a mean improvement of 1.00 logMAR units from the 
baseline (p < 0.001, 95 % CI 0.64–1.34). At 3 and 6 months 
follow up the BCVA was 1.46 ± 0.93 (20/576, range 20/20 to 
PL) and 1.57 ± 1.26 (20/743, range 20/20 to no PL) respec-
tively. The mean BCVA at the last post operative follow up 
visit was 1.73 ± 1.14 (20/1074, range 20/20 to no PL) with 
an improvement of 0.96 logMAR units from the baseline 
(p < 0.001, 95 % CI 0.54–1.37). The BCVA improved by two 
or more lines on ETDRS chart in 16 of 28 eyes (57.1 %), sta-
bilized or improved by less than two lines in nine (32.1 %) 
and worsened in three (10.7  %) at a mean follow up of 
14.28  months. The three eyes which worsened post-oper-
atively had a preoperative vision of hand movement which 
decreased to PL in one and loss of PL in the other two eyes. 
The results of visual outcome have been summarized in 
Table 2. The trend of BCVA change from baseline preopera-
tive to post operative last visit is shown in Fig. 1.
Prior to surgery, five study eyes had been treated with 
intravitreal bevacizumab, one received intravitreal tri-
amcinolone, three had undergone focal laser treatment, 
two eyes had undergone sclera buckling in the same eye 
in the past and three eyes had a history of photo dynamic 
therapy (PDT). Three patients in whom B-scan showed 
exudative retinal detachment were treated with oral ster-
oids preoperatively. Nine (33.3  %) patients had bilateral 
PCV of which four (14.8 %) also had associated VH with 
PCV in the fellow eye.
At presentation, fundus evaluation was not possible 
due to dense vitreous haemorrhage in 21 of the 28 eyes 
(75  %). B-scan showed vitreous haemorrhage in all 28 
eyes, extensive exudative retinal detachment in six and 
suspected mass lesion in one eye. Diagnosis of underlying 
cause being PCV was based on demonstration of polyps 
or branching vascular on previous or post operative ICG-
Angiography (ICG-A) in seven study eyes, four fellow 
eyes (Fig. 2) and on fluorescein angiography in two study 
eyes. The rest of the cases were diagnosed on the basis of 
presence of multiple sero-sanguinous RPE detachments 
suggestive of PCV. Two of the cases where polyps had 
been demonstrated on ICG-A before VH had regression 
of the previously noted polyps, but developed polyps in 
new locations subsequently (Fig. 3).
The site of subretinal haemorrhage was found to be 
predominantly macular in 12 (42.8 %) eyes, peripapillary 
in 4 (14.2 %) eyes, midperipheral in 10 (35.7 %) eyes and 
peripheral in 1 (3.5 %) eye. Intraoperatively, macular scar 
was noted in 9 (32.1 %) eyes and organized dehemoglobi-
nized blood at the macula was noted in seven (25 %) eyes.
The most common surgical complication was iatrogenic 
retinal break which was seen in 5 (17.8  %) eyes, which 
occurred typically during induction of posterior vitre-
ous detachment (PVD). Postoperatively, 10 (35.7 %) eyes 
developed visually significant cataract, 3 (10.7  %) eyes 
developed recurrent vitreous haemorrhage, 5 (17.8 %) had 
retinal detachment and 1 (3.5  %) patient had choroidal 
detachment. The mean IOP at baseline was 13.64 ± 2.52 
and 13.57 ± 4.12 mm Hg at the last follow up.
Table 2 Surgical management and postoperative outcome
BCVA best-corrected visual acuity, PL perception of light, VH vitreous 
hemorrhage
1. Baseline BCVA at presentation 2.69 ± 0.57 (<20/2000)
2. BCVA at 1 months postopera-
tive visit improvement from 
baseline
1.65 (SD 0.93, 20/800, p = 0.001), 
range 20/20 to no PL, 0.99 
logMAR units, (p = < 0.001, 95 % 
CI 0.64–1.34)
3. BCVA at 6 months postopera-
tive visit
1.53 (SD 1.2, 20/600, p = 0.0001), 
range 20/20 to no PL
4. Improvement from baseline 
to last visit
0.96 logMAR units, (p < 0.0001, 
95 % CI 0.54–1.37)
5. Mean follow up 14.8 months (range 1–84 months)
6. BCVA improved by two lines 
or more than presenting VA 
at last follow up
16 of 28 eyes (57.1 %)
7. BCVA worsened at last follow 
up than baseline BCVA
3 of 28 eyes (10.7 %)
8. Complications Cataract (n = 10), macular scar 
(n = 4), organised dehemoglo-
binised blood/exudates (n = 7), 
retinal detachment (n = 5), 
iatrogenic retinal breaks (n = 5), 
recurrent VH (n = 3), choroidal 
detachment (n = 1)
Fig. 1 Scatter plot comparing pre-operative and post-operative 
best-corrected visual acuity
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Discussion
Several reports and case series describing the diverse 
clinical spectrum, natural course, and role of various 
modalities of treatments for exudative PCV have been 
published in the last three decades [1, 2, 6–9, 11, 12], but 
there are few reports in the literature on the management 
of vitreous haemorrhage associated with PCV [6, 8, 9, 
13]. Vitreous haemorrhage associated with PCV differs 
from other manifestations of PCV as these eyes are not 
amenable to ICG angiography. Unless the affected eye has 
been previously diagnosed as PCV or the fellow eye has 
features of PCV, it is difficult to diagnose them. B-scan 
features that can differentiate vitreous haemorrhage sec-
ondary to PCV from other causes has been reported and 
are very useful in this situation. B-scan can demonstrate 
defining features like blood lining an elevated membrane, 
hemorrhagic pigment epithelial detachment and absence 
of any acoustic shadowing. The natural course or role of 
any treatment modality is unknown for vitreous haemor-
rhage in PCV as no large series of cases has been studied.
In our study, PCV was bilateral in 9 (33.3 %) of which 
four eyes (14.8  %) also had PCV associated vitreous 
haemorrhage in the fellow eye. Previously, bilaterality 
has been reported ranging from 9 to 47 % for exudative 
PCV [1, 8, 9, 12, 14]. PCV had been originally reported 
in hypertensive middle aged African women [8, 14–16]. 
Associated systemic hypertension has been reported 
in 18–88  % in various case series and clinic pathologi-
cal studies of PCV [8, 9, 14]. In our series, 59  % of the 
patients had systemic hypertension.
Vitreous haemorrhage associated with PCV has also 
been reported to occur following PDT [7, 17]. In our 
series only one patient had history of recent PDT and 
developed sudden onset loss of vision and VH 1  week 
after the treatment.
The earliest descriptions of vitreous haemorrhage in 
PCV was in 1985 [9, 10]. In previous reports by Kleiner 
et al. and Perkovich et al. [8, 9], visual recovery after vit-
rectomy was found to be equivocal. Two of the three eyes 
gained useful vision in one series [8], whereas the other 
studies reported worsening or no change in the visual 
acuity [4, 9]. These studies had small series ranging from 
one to three eyes that underwent vitrectomy. Recent 
reported outcomes of vitrectomy in PCV did not find a 
higher incidence of retinal breaks [13, 18].
In our study, significant visual improvement occurred 
in 16 of 29 eyes (57.1  %). Three patients recovered a 
visual acuity of better than 20/40, one eye had a visual 
Fig. 2 Top row shows polypoidal lesions (white arrows) demonstrated on indocyanine green angiography (ICG-A) in three study eyes done post-
operatively after clearing of vitreous hemorrhage. Bottom row shows ICG-A of fellow eyes in three cases where the ocular media in the study eyes 
did not clear postoperatively to allow an angiography and the basis of diagnosis was demonstration of polypoidal lesions (white arrows) and/or 
choroidal branching vascular network (white arrow heads) in the fellow eye
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acuity of 20/20 at 84  months, another had 20/25 at 
17 months and the third eye had 20/40 at 6 months fol-
low up. The improvement in visual acuity could have 
been limited by extensive blood under the macula. We 
did not attempt to remove the subretinal blood in our 
study. All cases in our study would have required sub-
retinal tissue plasminogen activator with incubation of 
approximately half an hour. In our experience, the blood 
decolorizes rapidly in these cases and does not liquefy 
with conventional doses of tPA. In such cases, the dose 
of tPA is much more than the recommended upper limit 
of 50 μg. Further, washing of blood in such massive hem-
orrhage under the macula tends to cause photorecep-
tor damage. The peripheral visual field would also have 
improved after the clearance of vitreous haemorrhage 
but would be difficult to document in most cases due to 
poor central fixation.
The commonest intra operative complication was iatro-
genic retinal breaks, which occurred during induction of 
PVD which was also been reported by us in our previous 
study [6]. Hence it is possibly better to wait for spontane-
ous PVD to occur before attempting surgery. The cases 
which had no visual recovery or experienced worsening 
of vision had macular scar, recurrent VH, post operative 
retinal detachment and cataract.
In a few cases in our study, polypoidal lesions which 
were seen on ICG-A before vitreous haemorrhage were 
not seen postoperatively but new lesions polypoidal 
lesions developed in a new location on subsequent fol-
low up (Fig. 3). This disappearance of classic polypoidal 
Fig. 3 Both eyes of a 60 year old male with bilateral polypoidal choroidal vasculopathy (PCV) associated with vitreous hemorrhage (VH). Left top 
picture shows the fundus picture of the left eye at baseline before VH showing serous pigment epithelial detachment (PED, white arrow) and subreti-
nal old blood. Top centre picture shows hemorrhagic pigment epithelial detachment (white arrowhead) and elevated orange yellow lesion before VH 
(white arrow). Top right picture shows fundus of the left eye post vitrectomy showing macular scar (white arrowhead), disappearance of previously 
seen polyp and development of a new orange elevated lesion (white arrow). Middle right indocyanine green angiography (ICG-A) of the left eye 
shows polypoidal lesions (white arrowheads) before VH. Middle centre shows ICG-A of the left eye after vitrectomy for VH shows disappearance of 
polyps and scar alone (white arrowhead). Middle right shows preoperative and postoperative OCT showing improvement of PED and resolution of 
intraretinal fluid. Bottom right fundus picture shows PED (white arrowhead). Bottom centre shows ICG angiography done before development of VH 
shows a polypoidal lesion (white arrow) and a PED (white arrowhead) and bottom left picture shows serosanguinous retinal detachment (arrow)
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lesions and replacement by RPE atrophy and scarring has 
been described in previously reported cases [1, 9]. The 
development of the haemorrhagic PEDs from the pre-
existing polypoidal lesions, followed by breakthrough VH 
and then subsequent scarring may be the natural course 
of the condition.
Conclusion
Our study shows that vitrectomy can produce significant 
visual improvement in patients with vitreous haemor-
rhage due to PCV. The incidence of retinal breaks during 
vitrectomy is high in PCV, and caution should be exer-
cised while inducing PVD in such cases.
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